5. Akutt lymfoblastisk leukemi (ALL) og lymfoblastlymfom hos voksne

Abou Dalle, I., Moukalled, N., El Cheikh, J., Mohty, M., & Bazarbachi, A. (2024). Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions. Leukemia, 38(9), 1876-1884.

Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. O., Berti, E., Bhagat, G., Borges, A. M., ... Xiao, W. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 36(7), 1720-1748.

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-405.

Burke, P. W., Hoelzer, D., Park, J. H., Schmiegelow, K., & Douer, D. (2020). Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion. ESMO Open, 5(5)

Chalandon, Y., Rousselot, P., Chevret, S., Cayuela, J. M., Kim, R., Huguet, F., Chevallier, P., Graux, C., ... Dombret, H. (2024). Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia. Blood, 143(23), 2363-2372.

Cortelazzo, S., Ferreri, A., Hoelzer, D., & Ponzoni, M. (2017). Lymphoblastic lymphoma. Critical Reviews in Oncology/Hematology, 113, 304-317.

Dunleavy, K., Pittaluga, S., Shovlin, M., Steinberg, S. M., Cole, D., Grant, C., Widemann, B., Staudt, L. M., ... Wilson, W. H. (2013). Low-intensity therapy in adults with Burkitt's lymphoma. New England Journal of Medicine, 369(20), 1915-25.

George, B. S., Yohannan, B., Gonzalez, A., & Rios, A. (2022). Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies. Biomedicines, 10(8)

Giebel, S., Czyz, A., Ottmann, O., Baron, F., Brissot, E., Ciceri, F., Cornelissen, J. J., Esteve, J., ... Nagler, A. (2016). Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 122(19), 2941-2951.

Gökbuget, N. (2013). How I treat older patients with ALL. Blood, 122(8), 1366-75.

Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M. S., ... Bargou, R. C. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood, 131(14), 1522-1531.

Hoelzer, D., Walewski, J., Dohner, H., Viardot, A., Hiddemann, W., Spiekermann, K., Serve, H., Duhrsen, U., ... Gökbuget, N. (2014). Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood, 124(26), 3870-9.

Jabbour, E., Kantarjian, H. M., Aldoss, I., Montesinos, P., Leonard, J. T., Gomez-Almaguer, D., Baer, M. R., Gambacorti-Passerini, C., ... Ribera, J. M. (2024). Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA : the journal of the American Medical Association, 331(21), 1814-1823.

Jabbour, E., Sasaki, K., Ravandi, F., Huang, X., Short, N. J., Khouri, M., Kebriaei, P., Burger, J., ... Kantarjian, H. M. (2018). Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer, 124(20), 4044-4055.

Kantarjian, H., Short, N. J., Jain, N., Sasaki, K., Huang, X., Haddad, F. G., Khouri, I., DiNardo, C. D., ... Jabbour, E. (2023). Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. American journal of hematology, 98(3), 493-501.

Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S., ... Advani, A. S. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(8), 740-53.

Kim, R., Chalandon, Y., Rousselot, P., Cayuela, J. M., Huguet, F., Balsat, M., Passet, M., Chevallier, P., ... Clappier, E. (2024). Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study. Journal of Clinical Oncology, 42(26), 3140-3150.

Laetsch, T. W., Maude, S. L., Rives, S., Hiramatsu, H., Bittencourt, H., Bader, P., Baruchel, A., Boyer, M., ... Grupp, S. A. (2023). Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. Journal of Clinical Oncology, 41(9), 1664-1669.

Litzow, M. R., Sun, Z., Mattison, R. J., Paietta, E. M., Roberts, K. G., Zhang, Y., Racevskis, J., Lazarus, H. M., ... Tallman, M. S. (2024). Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. New England Journal of Medicine, 391(4), 320-333.

Malard, F., & Mohty, M. (2020). Acute lymphoblastic leukaemia. Lancet, 395(10230), 1146-1162.

Marjoncu, D., & Holman, K. (2023). The efficacy and cost-impact of rasburicase 3 mg versus 6 mg for the management of tumor lysis syndrome: A multicenter analysis. Journal of Oncology Pharmacy Practice, 29(4), 893-898.

Martell, M. P., Atenafu, E. G., Minden, M. D., Schuh, A. C., Yee, K. W., Schimmer, A. D., Gupta, V., & Brandwein, J. M. (2013). Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. British Journal of Haematology, 163(4), 458-64.

Martinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gökbuget, N., Topp, M. S., Fielding, A. K., Rambaldi, A., ... Stein, A. (2017). Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, 35(16), 1795-1802.

McBride, A., Lathon, S. C., Boehmer, L., Augustin, K. M., Butler, S. K., & Westervelt, P. (2013). Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. Pharmacotherapy, 33(3), 295-303.

Patel, B., Kirkwood, A. A., Dey, A., Marks, D. I., McMillan, A. K., Menne, T. F., Micklewright, L., Patrick, P., ... Fielding, A. K. (2017). Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia, 31(1), 58-64.

Peters, C., Dalle, J. H., Locatelli, F., Poetschger, U., Pichler, H., Sedlacek, P., ... Buechner, J. (2020). TBI or Chemotherapy Based Conditioning for Children and Adolescents with ALL: A Prospective Randomized Multicenter-Study 'Forum' on Behalf of the AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP (European Hematology Congress 2020. Abstract: S102). Hentet fra https://library.ehaweb.org/eha/2020/eha25th/294922/c.peters.tbi.or.chemotherapy.based.conditioning.for.children.and.adolescents.html

Pfeifer, H., Wassmann, B., Bethge, W., Dengler, J., Bornhauser, M., Stadler, M., Beelen, D., Vucinic, V., ... Gmall Study Group (2013). Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia, 27(6), 1254-62.

Quist-Paulsen, P., Horvei, L., Dalgaard, J., Moksnes, M., Eilertsen, A. L., Paulson, M., Azrakhsh, N. A., Majeed, W., & Wik, H. S. (2025). Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study. British Journal of Haematology, 207(6), 2434-2440.

Quist-Paulsen, P., Toft, N., Heyman, M., Abrahamsson, J., Griskevicius, L., Hallbook, H., Jonsson, O. G., Palk, K., ... Schmiegelow, K. (2020). T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia, 34(2), 347-357.

Roloff, G. W., Aldoss, I., Kopmar, N. E., Lin, C., Dekker, S. E., Gupta, V. K., O'Connor, T. E., Jeyakumar, N., ... Rocca Consortium (2024). Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. Journal of Clinical Oncology, 43(5), 558-566.

Roschewski, M., Dunleavy, K., Abramson, J. S., Powell, B. L., Link, B. K., Patel, P., Bierman, P. J., Jagadeesh, D., ... Wilson, W. H. (2020). Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. Journal of Clinical Oncology, 38(22), 2519-2529.

Saini, N., Marin, D., Ledesma, C., Delgado, R., Rondon, G., Popat, U. R., Bashir, Q., Hosing, C. M., ... Kebriaei, P. (2020). Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood, 136(15), 1786-1789.

Sasaki, K., Jabbour, E. J., Ravandi, F., Short, N. J., Thomas, D. A., Garcia-Manero, G., Daver, N. G., Kadia, T. M., ... Kantarjian, H. M. (2016). Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 122(23), 3650-3656.

Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., ... Houot, R. (2021). KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, 398(10299), 491-502.

Toft, N., Birgens, H., Abrahamsson, J., Griskevicius, L., Hallbook, H., Heyman, M., Klausen, T. W., Jonsson, O. G., ... Schmiegelow, K. (2018). Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia, 32(3), 606-615.

Vora, A., Goulden, N., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., Moorman, A. V., & Wade, R. (2014). Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncology, 15(8), 809-18.